ArticleBMJ open2020

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease.

Takaomi Kessoku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.